Companies that own ArQule Inc.
First Eagle Investment Management LLC
15,081,128
13.86%
247,644
0.13%
06/30/2018
Nantahala Capital Management LLC
12,222,130
11.23%
0
5.82%
06/30/2018
BVF Partners LP
7,447,912
6.84%
-8,989,000
3.33%
06/30/2018
BlackRock Fund Advisors
4,956,695
4.55%
2,867,074
0%
06/30/2018
Millennium Management LLC
4,175,644
3.84%
2,448,660
0.04%
06/30/2018
The Vanguard Group, Inc.
3,589,291
3.3%
830,975
0%
06/30/2018
Renaissance Technologies LLC
2,860,683
2.63%
363,510
0.02%
06/30/2018
Menora Mivtachim Insurance Ltd.
2,159,697
1.99%
2,159,697
0.38%
06/30/2018
Sphera Funds Management Ltd.
1,497,683
1.38%
-766,453
1.44%
06/30/2018
SSgA Funds Management, Inc.
1,442,422
1.33%
1,411,624
0%
06/30/2018
| Address |
One Wall Street
Burlington Massachusetts 01803
United States
|
|
Employees
|
- |
| Website |
http://www.arqule.com |
| Updated |
07/08/2019 |
| ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of targeted therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751, ARQ 761. |
